fentanyl transdermal system

The Mylan Fentanyl Transdermal System is a generic version of the Duragesic patch, developed by Mylan Pharmaceuticals Inc (now part of Viatris) for the management of severe chronic pain in opioid-tolerant patients. It is a small molecule synthetic opioid agonist that primarily targets the mu-type opioid receptor. Unlike the original reservoir-type Duragesic patches, Mylan's version utilizes a solid matrix design where the fentanyl is integrated into a silicone adhesive layer sandwiched between a backing film and a protective liner. This design allows for a thinner, smaller patch compared to equivalent reservoir-based products. It is designed for continuous systemic delivery of fentanyl over a 72-hour period and was approved by the FDA in 2005 after demonstrating bioequivalence and therapeutic equivalence to the reference drug.

Other names

Mylan Fentanyl Transdermal Systemfentanyl patch (Mylan)